Objectives
To Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications
Description
-
Randomised, double-blinded, placebo-controlled study
-
2 treatment groups
-
Placebo
-
450 mg of CD388 antiviral conjugate
-
Trial length
29 weeks
Participant age
Participant must be ages 12 years and older
Patient eligibility
-
Participants must have a weight ≥ 40kg
-
Participants must have a BMI ≥ 18kg/m2
-
Participants must not have been diagnosed with influenza within the past 6 months
-
Female participants must NOT be pregnant
-
Female participants must NOT be breastfeeding
-
Participants will be divided into two primary strata (high risk non-immunocompromised and immunocompromised) - please speak to study staff regarding eligibility
Study requirements
5 onsite visits + 3 phone call visits
*Travel is reimbursed for each visit
** Please contact site for further information regarding eligibility
Get in touch with us
Our friendly team would love to hear from you!